Table 1 Characteristics of the patients included in the cohort

From: Patient satisfaction and amenorrhea rate after endometrial ablation by ThermaChoice III or NovaSure: a retrospective cohort study

	NovaSure	ThermaChoice III	p value
	298 patients	216 patients	p value
Age (years)	42.5 ± 4.9	42.3 ± 5.1	0.567
Parity	2.0 ± 1.0	2.3 ± 1.3	0.001
Previous treatment for HMB	212 (71)	175 (81)	0.010
>1 previous treatments	85 (29)	85 (39)	0.010
LNG-IUS	109 (37)	97 (45)	0.057
Oral contraceptives	143 (48)	106 (49)	0.808
Other drugs	61 (21)	59 (27)	0.070
Endometrial ablation	2 (1)	12 (6)	0.010
Number of myomata	0.3 ± 0.7	0.3 ± 0.7	0.213
Size of myoma (mm)	24.0 ± 11.2	23.3 ± 10.4	0.810
Subsereus	11 (4)	10 (5)	0.554
Intramural	32 (11)	29 (14)	0.305
Submuceus	5 (2)	2 (1)	0.705
Sound length (cm)	9.0 ± 1.0	9.0 ± 1.9	0.787
Filling balloon (ml)		20.4 ± 10.3
Power (W)	98.7 ± 27.1
Duration of current (s)	98.9 ± 19.9

Mean ± standard deviation or frequency (%). Other drugs = goserelin, leuprorelin, lynestrenol, medroxyprogesteron, norethisterone, and transexamic acid
HMB heavy menstrual bleeding, LNG-IUS levonorgestrel-intrauterine system
p-value < 0.05 was considered significant

Back to article page